256 related articles for article (PubMed ID: 6784924)
1. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
[TBL] [Abstract][Full Text] [Related]
2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
3. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
Ostrow S; Egorin M; Aisner J; Bachur N; Wiernik PH
Cancer Clin Trials; 1980; 3(1):23-7. PubMed ID: 7190082
[TBL] [Abstract][Full Text] [Related]
4. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
Majumdar SR; Kjellstrand CM; Tymchak WJ; Hervas-Malo M; Taylor DA; Teo KK
Am J Kidney Dis; 2009 Oct; 54(4):602-9. PubMed ID: 19535188
[TBL] [Abstract][Full Text] [Related]
5. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
Al-Sarraf M; Fletcher W; Oishi N; Pugh R; Hewlett JS; Balducci L; McCracken J; Padilla F
Cancer Treat Rep; 1982 Jan; 66(1):31-5. PubMed ID: 6796269
[TBL] [Abstract][Full Text] [Related]
7. Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis.
Frick GA; Ballentine R; Driever CW; Kramer WG
Cancer Treat Rep; 1979 Jan; 63(1):13-6. PubMed ID: 421230
[TBL] [Abstract][Full Text] [Related]
8. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
Campbell AB; Kalman SM; Jacobs C
Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
10. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).
DeSimone PA; Yancey RS; Coupal JJ; Butts JD; Hoeschel JD
Cancer Treat Rep; 1979 Jun; 63(6):951-60. PubMed ID: 466654
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.
Bajorin DF; Bosl GJ; Alcock NW; Niedzwiecki D; Gallina E; Shurgot B
Cancer Res; 1986 Nov; 46(11):5969-72. PubMed ID: 3756934
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
[TBL] [Abstract][Full Text] [Related]
13. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
14. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats.
Pera MF; Zook BC; Harder HC
Cancer Res; 1979 Apr; 39(4):1269-78. PubMed ID: 421210
[No Abstract] [Full Text] [Related]
15. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
Izumi T
Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
[TBL] [Abstract][Full Text] [Related]
16. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study.
Paterna S; Di Pasquale P; Parrinello G; Fornaciari E; Di Gaudio F; Fasullo S; Giammanco M; Sarullo FM; Licata G
J Am Coll Cardiol; 2005 Jun; 45(12):1997-2003. PubMed ID: 15963399
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).
Belt RJ; Himmelstein KJ; Patton TF; Bannister SJ; Sternson LA; Repta AJ
Cancer Treat Rep; 1979; 63(9-10):1515-21. PubMed ID: 498151
[TBL] [Abstract][Full Text] [Related]
18. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats.
Nagai N; Ogata H
J Pharm Sci; 1996 Jul; 85(7):720-4. PubMed ID: 8818996
[TBL] [Abstract][Full Text] [Related]
19. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A
Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
